Search
Traws Pharma Inc
TRAWAdd to Watchlist
0.768USD
-0.043-5.34%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
7.80MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-5.34%
5 Days
-7.17%
1 Month
-48.13%
6 Months
-42.28%
Year to Date
-32.06%
1 Year
-47.06%
Key Figures
0.820Open
0.850High
238.59KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.35%Turnover Ratio
0.811Prev. Close
0.757Low
141.61KTurnover
LossP/E Static
-1.47P/B
0.00%Div Yield TTM
-142.75%ROA
3.26552wk High
1.73Volume Ratio
-54.67MNet Profit
10.16MShares
-1.8659EPS TTM
1.47Beta
-4037.74%ROE
0.99552wk Low
11.45%Amplitude
100.00%Gross Margin
7.80MMarket Cap
-5.98Reward/Risk
7.56%Risk Rate
TradingKey Stock Score of Traws Pharma Inc
Currency: USD Updated: 2026-07-02Key Insights
Traws Pharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 1.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Traws Pharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Traws Pharma Inc Highlights
StrengthsRisks
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1134.51% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.79M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -0.41, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.52M shares, increasing 23.92% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.37.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
1.000
Target Price
+23.30%
Upside Space
Traws Pharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Traws Pharma Inc Info
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
Ticker SymbolTRAW
CompanyTraws Pharma Inc
CEODukes (Iain D)
Websitehttps://www.trawspharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Traws Pharma Inc (TRAW)?
The current price of Traws Pharma Inc (TRAW) is 0.77.
What is the symbol of Traws Pharma Inc?
The ticker symbol of Traws Pharma Inc is TRAW.
What is the 52-week high of Traws Pharma Inc?
The 52-week high of Traws Pharma Inc is 3.27.
What is the 52-week low of Traws Pharma Inc?
The 52-week low of Traws Pharma Inc is 0.99.
What is the market capitalization of Traws Pharma Inc?
The market capitalization of Traws Pharma Inc is 7.80M.
Is Traws Pharma Inc (TRAW) currently rated as Buy, Hold, or Sell?
According to analysts, Traws Pharma Inc (TRAW) has an overall rating of signal_hold, with a price target of 1.00.
What is the Earnings Per Share (EPS TTM) of Traws Pharma Inc (TRAW)?
The Earnings Per Share (EPS TTM) of Traws Pharma Inc (TRAW) is 0.83.